Insulet Offers Welcome Program for Animas® Users to Try Omnipod® Insulin Management System at Zero Cost
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171006005566/en/
"We are offering this program to help ensure people with diabetes have a
choice when it comes to their treatment options," said
The Omnipod System is designed for all insulin-requiring patients and is
the number one pediatric preferred pump in
Animas users can experience these benefits through Insulet's Welcome Program, which includes a free Omnipod System, built-in blood glucose meter, and 30 days of supplies at zero cost.
For full offer details and to get started, Animas patients should call the Customer Care Team at 1-888-643-8763. Offer terms and conditions are subject to change. Please click here to access the flyer with additional promotion details.
1 dQ&A Q3 2016
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 28, 2017 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
© 2017 Insulet Corporation and Omnipod are trademarks or registered trademarks of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.
Investor Relations and Media Contact:
Vice President, Investor Relations and Corporate Communications
News Provided by Acquire Media